Sunday , June 25 2017
Home / Precision Medicine

Precision Medicine

Study Estimates Breast and Ovarian Cancer Risk Linked to Faulty BRCA Genes

A new study has estimated the ages at which women with faults in two particular genes are most at risk of developing breast and ovarian cancer. The research found that the highest rates of breast cancer in women with a faulty BRCA1 gene were seen between the ages of 41-50. …

Read More »

New Three-In-One Blood Test Opens Door to Precision Medicine for Prostate Cancer

Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes. By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to …

Read More »

Newly Discovered Cellular Pathway May Lead to Cancer Therapies

Scientists have discovered a new cellular pathway that can promote and support the growth of cancer cells. In a mouse model of melanoma, blocking this pathway resulted in reduction of tumor growth. The study, which appears in Science, offers a novel opportunity to develop drugs that could potentially inhibit this …

Read More »

Study Sheds New Light on Inherited Testicular Cancer Risk

PHILADELPHIA – An analysis of data from five major studies of testicular cancer has identified new genetic locations that could be susceptible to inherited testicular germ cell tumors. The findings, which researchers call a success story for genome mapping, could help doctors understand which men are at the highest risk …

Read More »

ASCO and Foundation Medicine Collaborate to Identify Participants for the Targeted Agent & Profiling Utilization Study

ALEXANDRIA, Va. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–The American Society of Clinical Oncology, Inc. (ASCO) and Foundation Medicine (NASDAQ: FMI) today announced entry into an agreement to create efficiencies for research sites participating in ASCO’s TAPUR™ Study in identifying potential participants for the study. ASCO is announcing that reports from Foundation Medicine’s …

Read More »

ASCO 2017: Ovarian Cancer Drug Delivers ‘Very Promising’ Results in Early Trial

A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumors in half of women with the disease. Researchers believe the drug, which mimics the action of folic acid to enter cells, could hold huge promise for women with advanced ovarian …

Read More »

Philips and MSK Enter Partnership on Genome Analytics for Prostate Cancer Precision Medicine

AMSTERDAM and NEW YORK, June 1, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center, today announced a research collaboration to help improve the understanding of pancreatic cancer and …

Read More »

Advances in Personalized Medicine and Immuno-Oncology Fueled Major Shift in Cancer Treatment

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–During the past decade, advances in personalized medicine and immuno-oncology have fueled a major shift in treatment of cancer. Since 2011, 68 novel therapies have been approved across 22 cancer indications globally. These developments have led to more options as well as greater …

Read More »

Two Biomarkers Appear to Predict Course of Idiopathic Pulmonary Fibrosis

ATS 2017, WASHINGTON, DC — Two T cell biomarkers appear to predict the survival trajectory of patients with idiopathic pulmonary fibrosis (IPF), a lung disease that has a varied, but ultimately devastating, impact on patients, according to new research presented at the ATS 2017 International Conference. T-cells marshal the body’s …

Read More »

Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer

ASCO Perspective “This study identifies a subset of patients with lung cancer who can benefit from a targeted treatment that causes far fewer side effects than chemotherapy,” said ASCO President-Elect Bruce E. Johnson, MD, FASCO. “It’s also clear evidence that we can use precision medicine not only in patients with …

Read More »